N3-substituted temozolomide analogs overcome methylguanine-DNA methyltransferase and mismatch repair precipitating apoptotic and autophagic cancer cell death

Oncology (Switzerland)

Volumn 88, Issue 1, 2015, Pages 28-48

  Zhang, Jihong ^a   Hummersone, Marc ^b   Matthews, Charles S ^b   Stevens, Malcolm F G ^b   Bradshaw, Tracey D ^b  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Apoptosis; Autophagy; Glioblastoma multiforme; Methylguanine DNA methyltransferase; Mismatch repair; Temozolomide

Indexed keywords

ACRIDINE ORANGE; BAFILOMYCIN; DNA METHYLTRANSFERASE; METHYLGUANINE DNA METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; H2AFX PROTEIN, HUMAN; HISTONE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CELL CYCLE S PHASE; CELL LYSATE; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG SYNTHESIS; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE MICROSCOPY; G2 PHASE CELL CYCLE CHECKPOINT; GLIOMA CELL LINE; GROWTH INHIBITION; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNODETECTION; IN VITRO STUDY; MISMATCH REPAIR; MTT ASSAY; PRIORITY JOURNAL; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION; VECTOR CONTROL; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL CYCLE; CELL PROLIFERATION; DRUG EFFECTS; GLIOBLASTOMA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DACARBAZINE; DNA BREAKS, DOUBLE-STRANDED; DNA MISMATCH REPAIR; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; GLIOBLASTOMA; HISTONES; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84925285758     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000366131     Document Type: Article

References (46)

1. Denny BJ, Wheelhouse RT, Stevens MF, Tsang LL, Slack JA: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA . Biochemistry 1994; 33: 9045-9051
2. Tisdale MJ: Antitumor imidazotetrazines. 15. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones . Biochem Pharmacol 1987; 36: 457-462
3. Denny BJ, Wheelhouse RT, Stevens MFG, Tsang LLH, Slack JA: NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA . Biochemistry 1994; 33: 9045-9051
4. Pegg AE, Dolan ME, Moschel RC: Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase . Prog Nucleic Acid Res Mol Biol 1995; 51: 167-223
5. Pieper RO: Understanding and manipulating O6-methylguanine-DNA methyltransferase expression . Pharmacol Ther 1997; 74: 285-297
6. Irving JAE, Hall AG: Mismatch repair defects as a cause of resistance to cytotoxic drugs . Expert Rev Anticancer Ther 2001; 1: 149-158
7. Zhang J, Stevens MF, Bradshaw TD: Temozolomide: mechanisms of action, repair and resistance . Curr Mol Pharmacol 2012; 5: 102-114
8. Verbeek B, Southgate TD, Gilham DE, Margison GP: O6-methylguanine-DNA methyltransferase inactivation and chemotherapy . Br Med Bull 2008; 85: 17-33
9. Dolan ME, Moschel RC, Pegg AE: Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents . Proc Natl Acad Sci USA 1990; 87: 5368-5372
10. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, Margison GP: Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors . Clin Cancer Res 2006; 12: 1577-1584
11. Woolford LB, Southgate TD, Margison GP, Milsom MD, Fairbairn LJ: The P140K mutant of human O(6)-methylguanine-DNA-methyttransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O(6)-(4-bromothenyl)guanine . J Gene Med 2006; 8: 29-34
12. Tentori L, Graziani G: Pharmacological strategies to increase the antitumor activity of methylating agents . Curr Med Chem 2002; 9: 1285-1301
13. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Newell DR: Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells . Clin Cancer Res 2004; 10: 881-889
14. Kotandeniya D, Murphy D, Seneviratne U, Guza R, Pegg A, Kanugula S, Tretyakova N: Mass spectrometry based approach to study the kinetics of O6-alkylguanine DNA alkyltransferase-mediated repair of O6-pyridyloxobutyl-2'-deoxyguanosine adducts in DNA . Chem Res Toxicol 2011; 24: 1966-1975
15. Mohammed MZ, Vyjayanti VN, Laughton CA, Dekker LV, Fischer PM, Wilson DMI, Madhusudan S: Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines . Br J Cancer 2011; 104: 653-663
16. Stevens MFG, Cousin D, Jennings S, McCarroll A, Williams JG, Hummersone MG, Zhang J: 3-Substituted-4-oxo-3, 4-dihydro-imidazo [5, 1-d][1, 2, 3, 5]-tetrazine-8-carboxylic acid amides and their use. IPAN PCT/ GB2008/004140. International Patent Application No PCT/GB2008/004140. 2008
17. Zhang J, Stevens MF, Hummersone M, Madhusudan S, Laughton CA, Bradshaw TD: Certain imidazotetrazines escape O6-methylguanine-DNA methyltransferase and mismatch repair . Oncology 2011; 80: 195-207
18. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Zuckerbraun B: Guidelines for the use and interpretation of assays for monitoring autophagy . Autophagy 2012; 8: 445-544
19. Vogelstein B, Kinzler KW: p53 function and dysfunction . Cell 1992; 70: 523-526
20. Zhang J, Stevens MF, Laughton CA, Madhusudan S, Bradshaw TD: Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications . Oncology 2010; 78: 103-114
21. D'Atri S, Tentori L, Lacal PM, Graziani G, Pagani E, Benincasa E, Jiricny J: Involvement of the mismatch repair system in temozolomide-induced apoptosis . Mol Pharmacol 1998; 54: 334-341
22. Bradshaw TD, Hummersome M, Hartley J, Stevens MFG, Zhang J: N3-substituted temozolomide analogs overcome methylguanine DNA methyltransferase and mismatch repair (abstract 176). 21st EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Boston, 2010
23. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM: Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody . Radiat Res 2002; 158: 486-492
24. Hirose Y, Berger MS, Pieper RO: p53 effects both the duration of G2/M arrest and the fate of temozolomidetreated human glioblastoma cells . Cancer Res 2001; 61: 1957-1963
25. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine . Oncogene 2007; 26: 186-197
26. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage . Science 1998; 282: 1497-1501
27. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S: Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells . Cell Death Differ 2004; 11: 448-457
28. Klionsky DJ, Abeliovich H, et al: Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes . Autophagy 2008; 4: 151-175
29. Kondo Y, Kanzawa T, Sawaya R, Kondo S: The role of autophagy in cancer development and response to therapy . Nat Rev Cancer 2005; 5: 726-734
30. Eskelinen EL: To be or not to be?. Examples of incorrect identification of autophagic compartments in conventional transmission electron microscopy of mammalian cells . Autophagy 2008; 4: 257-260
31. Yamamoto A, Tagawa Y, Yoshimori T, Moriyama Y, Masaki R, Tashiro Y: Bafilomycin A1 prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes in rat hepatoma cell line, H-4-II-E cells . Cell Struct Funct 1998; 23: 33-42
32. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J, Wooster R: A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy . Cancer Res 2006; 66: 3987-3991
33. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Weller M: O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells . J Neurochem 2006; 96: 766-776
34. Fan S, el-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, O'Connor PM: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents . Cancer Res 1994; 54: 5824-5830
35. Fan S, Smith ML, Rivet DJ 2nd, Duba D, Zhan Q, Kohn KW, O'Connor PM: Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline . Cancer Res 1995; 55: 1649-1654
36. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents . Cell 1993; 74: 957-967
37. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents . Cancer Res 1997; 57: 4285-4300
38. Watanabe Y, Shibata K, Sugimura H, Maekawa M: p53-dependent change in replication timing of the human genome . Biochem Biophys Res Commun 2007; 364: 289-293
39. Zhukovskaya N, Branch P, Aquilina G, Karran P: DNA replication arrest and tolerance to DNA methylation damage . Carcinogenesis 1994; 15: 2189-2194
40. Zou Y, Wang Q, Li B, Xie B, Wang W: Temozolomide induces autophagy via ATM-AMPK-ULK1 pathways in glioma . Mol Med Rep 2014; 10: 411-416
41. Dalby K, Tekedereli I, Lopez-Berestein G, Ozpolat B: Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer . Autophagy 2010; 6: 322-329
42. Katayama M, Kawaguchi T, Berger MS, Pieper RO: DNA damaging agent-induced autophagy produces a cytoprotective adenosine triphosphate surge in malignant glioma cells . Cell Death Differ 2006; 14: 548-558
43. Eisenberg-Lerner A, Bialik S, Simon HU, Kimchi A: Life and death partners: apoptosis, autophagy and the crosstalk between them . Cell Death Differ 2009; 16: 966-975
44. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM: Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide . J Neurosurg 2003; 99: 1047-1052
45. Shingu T, Fujiwara K, Bogler O, Akiyama Y, Moritake K, Shinojima N, Kondo S: Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells . Int J Cancer 2009; 124: 1060-1071
46. Othman RT, Kimishi I, Bradshaw TD, Storer LC, Korshunov A, Pfister SM: Coyle B: Overcoming multiple drug resistance mechanisms in medulloblastoma. Acta Neuropathol Commun 2014; 2: 57